Insider Q&A: A Model for More Rational Drug Prices – Associated Press
Precision Health Economics’ Darius Lakdawalla speaks with the AP’s Matthew Perrone and offers some guidelines for drug pricing.
An Employer Education Initiative That Increased Comprehensive Contraception Coverage
This case study illustrates a successful program that led to 7 major national health plans offering the manufacturer’s top 2 brands at $0 out-of-pocket to the patient.
Real World Superiority Data May Not Be Enough To Boost GSK’s Breo In COPD – The Pink Sheet
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.
GSK Leads Way With Real World Data, But Others Follow – The Pink Sheet
Dan Renick comments on the importance of value demonstration for respiratory disease treatments in The Pink Sheet.
(more…)
What’s the Deal – The Wall Street Journal
Pharma Industry Firm Moves for More Space
Precision for Value, a company that helps bring pharmaceutical products to market, has found a larger home at One Grand Central Place.
Press Release: Peter Neumann, Leader in Health Economics and Outcomes Research, Joins Precision Health Economics as Advisor
Los Angeles, May 17, 2016 — Precision Health Economics (PHE), a global leader in health economic research, policy, and analytics, announced today that Peter Neumann, ScD has joined PHE in the role of principal scientific advisor.
A Novel Approach to Demonstrate How Patients Value New Oncology Therapies
In this study, the Precision Health Economics team quantifies how patients value new oncology therapies through research focused on 2 clinical contexts in advanced cancer: metastatic malignant melanoma and metastatic breast cancer.
Global Stakeholder Insights-Gathering Informs Optimal Biosimilar Pricing Strategies
A pharmaceutical manufacturer was preparing to launch 2 biosimilars with autoimmune disease indications across 6 European markets. With several access challenges for both products anticipated, this case study shares our approach to the assessment of likely access conditions and price potentials at launch, as well as the evidence generation needed to improve those scenarios across markets. The findings were critical to informing the development of a pricing strategy for both biosimilars.
How to Apply Objection-Handling to Drug Price Complaint – PM360
Dan Renick comments on the burden of out-of-pocket patient costs for specialty medications in PM360.
You Can’t Just Ban Twinkies (Darius Lakdawalla interview) – BBC Radio
Precision’s Lakdawalla on the BBC: ‘You can’t just ban Twinkies’
Precision’s Darius Lakdawalla was recently interviewed for the BBC’s Business Daily program, discussing the trend to ban large size sodas and other recent anti-junk food measures.
